Biomarkers for Mental Disorders

Today the diagnosis of most psychiatric disorders is based mainly on clinical examination. As in other fields of medicine, the identification of biological markers can provide a more objective access to diagnosis and it can help to confirm the clinical diagnosis. Biological markers may also allow to track disease progression and treatment success in an objective manner.

We therefore have a close cooperation with international research groups of the Cambridge Center for Neuropsychiatric Research CCNR der University of Cambridge (Head: Prof. Dr. Sabine Bahn, MD PhD) and the Schizophrenia Center and Program in Molecular Psychiatry – Johns Hopkins University, Baltimore, MD, USA (Director: Prof. Akira Sawa, MD PhD) to identify some biomarker profiles for psychiatric disorders. We were able to detect two first biomarkerprofiles in the cerebrospinal fluid (CSF) of patients with first-episode schizophrenic psychosis. These profiles are considered to be promising candidates for the development of generally available diagnostic tests.

Founded by the European Commission, we were able to continue our work as part of a European research project Mit Unterstützung der EU Kommission konnten wir in einem europäischen Forschungsprojekt (SchizDX).

We are currently continuing our biomarker research in collaboration with the Johns Hopkins University.

Funding: This research was funded by the Stanley Medical Research Institute of teh Theodore and Vada Stanley Foundation, USA (Grant IDs 01-315 and 03-NV-003 to FML) and European Commission (SchizDX EU FP7 HEALTH-F4-2009-223427).


Selected Publications

E. G. Severance, K. L. Gressitt, A. Alaedini, J. M. Bumb, J. K. Mueller, F. Enning, R. H. Yolken, F. M. Leweke: IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Br Behav Immunity (2015) 44:148-58.

L. N. Hayes, E. G. Severance, J. T. Leek, K. L. Gressitt, C. Rohleder, J. M. Coughlin, F. M. Leweke, R. H. Yolken, A. Sawa: Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull (2014) 40:963-972.

E. Schwarz, J. M. van Beveren, J. Ramsey, F. M. Leweke, M. Rothermundt, B. Bogerts, J. Steiner, P. C. Guest, S. Bahn: Identification of molecular subgroups of schizophrenia patients. Schizophr Bull (2014) 40:787-795.

J. Coughlin, K. Ishizuka, S.-I. Kano, J. Edwards, F. Seifuddin, M. Shimano, E. Daley, P. Zandi, F. M. Leweke, N. Cascella, M. Pomper, R. Yolken, A. Sawa: Marked reduction of soluble superoxide dis-mutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatr (2013) 18:10-11.

J. M. Ramsey, E. Schwarz, P. C. Guest, N. J. van Beveren, F. M. Leweke, M. Rothermundt, B. Bogerts, J. Steiner, L. Ruta, S. Baron-Cohen, S. Bahn: Molecular sex differences in human serum. PLoS One, 7 (2012), e51504.

E. Schwarz, P. C. Guest, H. Rahmoune, L. W. Harris, L. Wang, F. M. Leweke, M. Rothermundt, B. Bogerts, D. Koethe, L. Kranaster, P. Ohrmann, T. Suslow, G. McAllister, M. Spain, A. Barnes, N. J. van Beveren, S. Baron-Cohen, J. Steiner, F. E. Torrey, R. H. Yolken, S. Bahn: Identification of a biological signature for schizophrenia in serum. Mol Psychiatr (2012) 17: 494-502.

M. Herberth, D. Koethe, T. M. Cheng, N. D. Krzyszton, S. Schoeffmann, P. C. Guest, H. Rahmoune, L. W. Harris, L. Kranaster, F. M. Leweke, S. Bahn: Impaired glycolytic response in peripheral blood mo-nonuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol Psychiatr (2011) 16: 848-859.

Y. Levin, L. Wang, E. Schwarz, D. Koethe, F. M. Leweke, S. Bahn: Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatr (2010) 15: 1088-1100.

P. C. Guest, L. Wang, L.W. Harris, K. Burling, Y. Levin, A. Ernst, M. T. Wayland, Y. Umrania, M. Her-berth, D. Koethe, J. M. van Beveren, M. Rothermundt, G. McAllister, F. M. Leweke, J. Steiner, S. Bahn: Increased levels of circulating insulin-related peptides in first onset, antipsychotic naïve schizophrenia patients. Mol Psychiatr (2010) 15: 118-119.

M. Herberth, D. N. Krzyszton, D. Koethe, M. R. Craddock, E. Bulger, E. Schwarz, P. Guest, F. M. Le-weke, S. Bahn: Differential effects on T-cell function following exposure to serum from schizophrenia smokers. Mol Psychiatr (2010) 15: 364-371.

J. T.-J. Huang, L. Wang, M. Wengenroth, D. Koethe, C. W. Gerth, S. Gross, D. Schreiber, F. M. Lewe-ke, S. Bahn: Independent protein profiling studies show a decrease in apolipoprotein A1 levels in CSF and peripheral tissues. Mol Psychiatr (2008) 13: 1118-1128.

J. T.-J. Huang*, F. M. Leweke*, D. Oxley, L. Wang, N. Harris, D. Koethe, C. W. Gerth, B. M. Nolden, S. Gross, D. Schreiber, S. Bahn: Identification of diagnostic biomarkers for first-onset schizophrenia. PLoS Medicine (2006) 3(11): e428:1-14.

E. Holmes*, T. M. Tsang*, J. T.-J. Huang*, F. M. Leweke*, D. Koethe, C. W. Gerth, B. M. Nolden, S. Gross, D. Schreiber, S. Bahn: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Medicine (2006) 3(8), e327:1-9.

RG Translational Research in Psychiatry • Central Institute of Mental Health - Disclaimer